



Innovating Technologies for Life

6 June 2007

ITL Limited

ABN 16 088 212 088

PO Box 139

Fyshwick Canberra

ACT 2609 Australia

t: +61 2 6280 8535

f: +61 2 6280 8538

www.itl-limited.com

Market Update

The Board of Directors expects the company to achieve the following financial performance for the year:

Revenue	\$34.0 to \$35.0 million
Net profit	\$1.9 to \$2.2 million
EBITDA	\$3.2 to \$3.6 million

Revenue is expected to grow 10.0% from the previous year's performance of \$31.3 million, however the performance of the company in the second half has been flat.

The Australian Custom Procedure Pack (CPP) business has been adversely affected by capacity problems at its third party sterilisation contractor. These sterilisation constraints were advised to the market in October 2006 at ITL's AGM and again in February 2007 at the release of ITL's half year results. The effect of this has been largely felt in the second half.

The new state of the art Melbourne manufacturing facility is now fully operational, and with the imminent commissioning of ITL's on-site steriliser, this division is well placed to service the growing CPP market into the future.

Bill Mobbs
CEO

ITL (ASX: ITD, www.itl-limited.com) is a rapidly expanding and diversified company within the healthcare industry. Specialising in innovative medical devices and procedure packs for global healthcare markets, ITL manufactures in Australia and Malaysia, and has sales offices in Australia, North America, Europe and Asia.

ITL's patented medical devices have a presence in over 35 countries and protect healthcare workers in millions of procedures annually. ITL supplies its range of customised procedure packs to over 200 hospitals across Australia, and within Asia supplies procedure packs, capital equipment and instruments to over 160 hospitals.